Valeant enters into restated credit and guarantee agreement providing $3.1 billion revolving and term credit facilities

Lawyers Peter J. Wiazowski, Suzana A. Lobo, Aditya Rebbapragada, Sandro Muzzo

On February 13, 2012, Valeant Pharmaceuticals International, Inc. and certain of its subsidiaries entered into a third amended and restated credit and guaranty agreement, providing Valeant Pharmaceuticals International, Inc. with revolving facilities and term facilities in the aggregate principal amount of $3.1 billion. The transaction was entered into by Valeant Pharmaceuticals International, Inc., as the borrower, certain subsidiaries of Valeant Pharmaceuticals International, Inc., including V-BAC Holding Corp, Valeant Canada GP Limited and Valeant Canada S.E.C./Valeant Canada LP, as guarantors, Goldman Sachs Lender Partners LLC as administrative agent and collateral agent and a syndicate of lenders party thereto.

Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics in the United States, Canada, Latin America, Eastern and Central Europe, Australia, South East Asia and South Africa.

Valeant Pharmaceuticals International, Inc. and its subsidiaries were represented in Ontario, Quebec and Alberta by Norton Rose Canada LLP with a team comprising of Peter Wiazowski, Suzana Lobo, Aimee Halfyard, Aditya Rebbapragada, Sandro Muzzo and Taylor Wood.